Neurocrine Biosciences Inc (NASDAQ:NBIX) reported its fourth-quarter and full-year 2025 financial results, delivering robust sales growth that was slightly overshadowed by a narrow miss on bottom-line expectations. The company's flagship product continued to drive significant revenue, but the market's initial reaction in after-hours trading was negative, with shares declining approximately 3.2%.
Earnings Results Versus Estimates
The company's performance for the quarter ending December 31, 2025, presented a mixed picture when held against Wall Street's expectations.
- Revenue: The company reported Q4 revenue of $805.5 million. This came in just shy of the analyst consensus estimate of approximately $807.8 million, representing a marginal miss.
- Earnings Per Share (EPS): The non-GAAP EPS for the quarter was $1.88. This fell short of the estimated $1.93, marking a more noticeable deviation from forecasts.
For the full year 2025, the company announced total net product sales of $2.83 billion, representing a substantial 22% increase year-over-year. Fourth-quarter sales of $798.3 million also grew 29% compared to the same period in 2024.
Market Reaction and Price Action
The immediate market response to the earnings release was negative. The stock traded down over 3% in the after-hours session following the report. This price action suggests investor focus may have settled on the EPS miss and the slight revenue shortfall, potentially overlooking the strong underlying annual growth. Prior to the announcement, the stock had been relatively stable, showing modest gains over the past month.
Financial Outlook and Analyst Expectations
A key component of the earnings release was the company's provision of financial expectations for the full year 2026. Management's sales guidance will be a critical point of comparison for investors. Currently, the analyst consensus estimates for Neurocrine in 2026 are as follows:
- Full-Year 2026 Revenue Estimate: $3.47 billion
- Full-Year 2026 Sales Estimate: $3.47 billion
For the upcoming first quarter of 2026, analysts are projecting revenue of $1.48 billion and sales of $794.1 million. The degree to which the company's official 2026 guidance aligns with or diverges from these consensus figures will likely be a primary driver of the stock's direction in the near term.
Press Release Summary
The core announcement centered on the strong commercial performance of Neurocrine's product portfolio, led by INGREZZA, which fueled significant year-over-year growth. The press release detailed the full-year and fourth-quarter sales results, emphasized the company's financial position, and outlined its pipeline progress in neuroscience. A major focal point was the forward-looking financial expectations provided for 2026, which gives investors a new benchmark against which to measure the company's future execution.
For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can review the comprehensive data available on the Neurocrine Biosciences earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
